Sarcoma Clinical Trials

532 recruitingLast updated: June 17, 2026

There are 532 actively recruiting sarcoma clinical trials across 54 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3, Early Phase 1, Phase 4. Top locations include Houston, Texas, United States, New York, New York, United States, Los Angeles, California, United States. Updated daily from ClinicalTrials.gov.


Sarcoma Trials at a Glance

532 actively recruiting trials for sarcoma are listed on ClinicalTrialsFinder across 6 cities in 54 countries. The largest study group is Phase 2 with 212 trials, with the heaviest enrollment activity in Houston, New York, and Los Angeles. Lead sponsors running sarcoma studies include M.D. Anderson Cancer Center, National Cancer Institute (NCI), and Mayo Clinic.

Treatments under study

About Sarcoma Clinical Trials

Looking for clinical trials for Sarcoma? There are currently 123 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Sarcoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Sarcoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 532 trials

Recruiting

Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies

SarcomaEndocrine TumorsNeuroblastoma+2 more
National Cancer Institute (NCI)6,035 enrolled5 locationsNCT01109394
Recruiting
Phase 3

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

Metastatic Dedifferentiated LiposarcomaStage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8+3 more
National Cancer Institute (NCI)365 enrolled256 locationsNCT06422806
Recruiting

Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer

LymphomasMulticentric Castleman s DiseaseHIV+2 more
National Cancer Institute (NCI)1,029 enrolled1 locationNCT00006518
Recruiting
Phase 1

Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...

SarcomaPrecursor Cell Lymphoblastic Leukemia-LymphomaNeurofibroma, Plexiform+1 more
National Cancer Institute (NCI)54 enrolled1 locationNCT02390752
Recruiting
Phase 2

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Stage IV Renal Cell Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Large Cell Neuroendocrine Carcinoma+42 more
National Cancer Institute (NCI)314 enrolled578 locationsNCT03866382
Recruiting

Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis

Gastric CancerGastric NeoplasmGastrointestinal Stromal Tumor (GIST)+2 more
National Cancer Institute (NCI)400 enrolled1 locationNCT04557969
Recruiting
Not Applicable

Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers

Urothelial CarcinomaCervical CarcinomaCutaneous Melanoma+7 more
Institut Claudius Regaud450 enrolled1 locationNCT06967961
Recruiting
Phase 2Phase 3

A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

Metastatic OsteosarcomaHigh Grade OsteosarcomaLocalized Osteosarcoma+1 more
National Cancer Institute (NCI)1,122 enrolled197 locationsNCT05691478
Recruiting
Phase 1Phase 2

PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors

Refractory NeuroblastomaRefractory RhabdomyosarcomaRefractory Solid Tumors+3 more
Theodore Laetsch59 enrolled7 locationsNCT06721689
Recruiting
Phase 2

Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, The AXIOM Trial

Metastatic Alveolar Soft Part SarcomaAdvanced Soft Tissue SarcomaAdvanced Alveolar Soft Part Sarcoma+2 more
National Cancer Institute (NCI)27 enrolled13 locationsNCT05333458
Recruiting
Phase 1

Tumor Neoantigen Vaccine SarVac Combined With Tumor Specific Lymphocyte Reinfusion in the Treatment of Advanced Sarcoma

OsteosarcomaSoft Tissue Sarcoma (STS)
Sun Yat-sen University16 enrolled1 locationNCT07648069
Recruiting

Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease

Castleman's DiseaseKaposi's SarcomaHuman Immunodeficiency Virus+1 more
National Cancer Institute (NCI)280 enrolled1 locationNCT03300830
Recruiting
Not Applicable

Locally ablatiVe therApy in oLigO-pRogressive sOlid tUmorS (VALOROUS)

Breast CancerSarcomaHead and Neck Cancer+2 more
University of California, Davis250 enrolled1 locationNCT06103669
Recruiting
Phase 2

An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer

Clear Cell Renal Cell CarcinomaSarcomatoid Renal Cell CarcinomaStage III Renal Cell Cancer+2 more
Jonsson Comprehensive Cancer Center91 enrolled1 locationNCT06447103
Recruiting
Phase 2

Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

Rhabdomyosarcoma
St. Jude Children's Research Hospital135 enrolled3 locationsNCT06023641
Recruiting
Early Phase 1

N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy

Synovial SarcomaMyxoid LiposarcomaRound Cell Liposarcoma
Seth Pollack8 enrolled1 locationNCT07261657
Recruiting
Phase 1Phase 2

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

OsteosarcomaEwing SarcomaNeuroblastoma+4 more
Milton S. Hershey Medical Center289 enrolled10 locationsNCT06465199
Recruiting
Phase 1

Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)

Ewing Sarcoma
Amgen50 enrolled7 locationsNCT07297979
Recruiting
Phase 2

Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma

OsteosarcomaEwing SarcomaEwing Sarcoma Metastatic
Milton S. Hershey Medical Center406 enrolled2 locationsNCT07321912
Recruiting
Phase 2

Toripalimab Combined With CAV/IE Regimen

Soft Tissue Sarcoma
Sun Yat-sen University134 enrolled1 locationNCT04589741